Skip to main content
Premium Trial:

Request an Annual Quote

Migrations: Jan 30, 2009

Premium

The Massachusetts Life Sciences Center this week announced the addition of Jonathan Fleming, Doug Cole, and Jean George to the organization’s scientific advisory board, bringing the board’s total membership to fifteen.

Fleming is the managing general partner of Oxford Bioscience Partners. Prior to joining OBP in 1996, he was a founding general partner of MVP Ventures. He began his investment career with TVM Techno Venture Management. Fleming also co-founded Medica Venture Partners.

Cole is currently a general partner at Flagship Ventures. While at Flagship, Cole co-founded Ensemble Discovery with Noubar Afeyan and David Liu of Harvard University, and he served as chief executive officer of the company its initial stages.

He was previously medical director of Cytotherapeutics. Cole was then appointed program executive at Vertex Pharmaceuticals.

Jean George is a partner at Advanced Technology Ventures. Prior to joining ATV, George was a director at BancBoston Ventures. Previously, George held a variety of roles in marketing, product development, and business development at Genzyme, including vice president of global sales and marketing.

The Scan

Omicron's Emergence

The World Health Organization has called Omicron a SARS-CoV-2 "variant of concern," the Los Angeles Times writes.

Not as Much

Merck's pill to treat COVID-19 reduces the risk of hospitalization and death among COVID-19 patients by less than previously reported, the New York Times says.

Bats That Hang Together

Discover magazine writes that researchers have found a social microbiome among vampire bats.

PLOS Papers on CEWAS, Simian Varicella Virus Transcriptome, Dermatomyositis Markers

In PLOS this week: multi-omic approach to home in on genetic risk variants, transcriptomic analysis of the simian varicella virus, and more.